'No Frills Drugs' push Pharma to look for a cure

30 September 2009

The pharmaceutical industry is sharing the symptoms of the economic downturn. Counterfeit drug manufacturing and parallel trading is causing some serious side effects to the ailing industry and leaders from GlaxoSmithKline, Bayer, AstraZeneca, Novartis and Pfizer met at this year's NGP Summit to help come up with a cure.

The aims of the Summit were to enable these business leaders to review their current manufacturing technologies and allow them to concentrate resources on their core competences - developing new drugs.

'The structure of the conference provided an excellent framework for information exchange and networking'with recent trends showing a shift towards reducing waste and cost management ensuring brand security is of utmost importance. With technology moving at such a fast rate it is important that the pharmaceutical industry keeps up,' said Mike Bowley, GSK's senior technical director

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK